STOCK TITAN

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Sangamo Therapeutics, Inc. (SGMO) will release its Q4 and full-year 2023 financial results on March 13, 2024. A conference call will follow to discuss financial performance and business updates.
Positive
  • None.
Negative
  • None.

RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024.

The Company will hold a conference call at 4:30 p.m. Eastern on Wednesday, March 13, which will be open to the public. During the conference call, the company will review its financial results and provide business updates.

Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.

A replay will be available following the conference call, accessible under Events.

About Sangamo Therapeutics

Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo’s zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and Sangamo’s capsid discovery platform is expanding delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter/X.

Investor & Media Inquiries

Louise Wilkie

ir@sangamo.com

media@sangamo.com

Source: Sangamo Therapeutics, Inc.

FAQ

When will Sangamo Therapeutics release its Q4 and full-year 2023 financial results?

Sangamo Therapeutics will release its Q4 and full-year 2023 financial results on March 13, 2024.

What is the ticker symbol for Sangamo Therapeutics?

The ticker symbol for Sangamo Therapeutics is SGMO.

When is the conference call scheduled for discussing financial results and business updates?

The conference call is scheduled for 4:30 p.m. Eastern on Wednesday, March 13, 2024.

How can participants access the conference call?

Participants can register for the call using the provided link and either dial in with the passcode or use the dial-out option for instant connection.

Where can participants find the link to the live webcast?

The link to access the live webcast can be found on the Sangamo Therapeutics website in the Investors and Media section under Events.

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

SGMO Rankings

SGMO Latest News

SGMO Stock Data

108.31M
165.08M
9.45%
49.93%
5.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
RICHMOND

About SGMO

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.